Allogeneic cancer cell-based immunotherapy
US8475785B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2009 |
| Grant date | Jul 2, 2013 |
| Priority date | — |
| Expiry date | Oct 31, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.